AMGEN Message Board - Msg: 353757

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMGEN

AMGN 296.30

-0.7%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Nathan L. who wrote (37)	10/14/1996 2:05:00 PM
From: YOAV KEDAR	of 42

MGDF or "megakaryocyte growth and development factor" is a hormone that boots up the production of throbocytes or "blood platelets". amgen is developing it for thrombocytopenia secondary to chemotherapy (sharp decrease in the platelets count that leads to bleeding). the potential for the drug is an interesting issue - some in the medical community value the market for it in the 0.5-1 billion $ annualy. it will enable patients to recieve chemotherapy in higher doses. in my opinion, MGDF is currently "under estimated" by the investment community - maybe because of the competition it faces from Gennentech (with an almost identical molecule), and Genetic institute's interlukine 11. be nice if could expand my knowledge on chiron's pipe line. good lack with it.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next